Clarification Memo # 2 to:

HPTN 077: A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women, Version 2.0, dated November 18, 2014

Final Version: 09 February 2015

Summary of Revisions and Rationale

Revision 1: In Section 3.1, the word “and” has been changed to “or” to clarify the intent that reporting any one of the sexually transmitted infections listed in the last 12 months will prohibit entry in to the study.

Revision 2 a and b: The sponsor of the study, Division of AIDS/NIAID/NIH, on 06 February 2015 released an updated table to grade toxicities that occur in their sponsored studies. The updated table, Version 2.0, dated November 2014, will be used for the entire duration of this study. Sections 6.3 and 6.42 include clarifications regarding this updated table.

Implementation

The clarifications included in this memorandum have been approved by the Division of AIDS (DAIDS) Medical Officer and are to be implemented immediately upon each site’s respective study activation of Version 2.0 of the protocol. Investigational Review Board (IRB)/Ethics Committee (EC)/other regulatory entity approval of HPTN 077 Protocol Clarification Memo #2 to HPTN 077 V. 2.0 is not required by DAIDS; however, sites may submit it to the responsible IRBs/ECs/other regulatory entities for their information or, if required by the IRBs/ECs/other regulatory entities, for their approval prior to implementation.

None of the clarifications being made impact the sample informed consent forms, and the benefit-to-risk ratio for participants is not affected in any way.

The modifications included in this Clarification Memo will be incorporated into the next letter of amendment or full protocol amendment. Text appearing below in highlighted bold will be added, and text appearing in highlighted strike-through will be deleted.

Revision 1  Section 3.1: Inclusion Criteria

Note: Only the one bullet impacted by this clarification in this section is included below, under “In the last 12 months (at the time of screening):

- No self-reported diagnosis of GC, CT, incident syphilis, bacterial vaginosis, and or trichomoniasis
Revision 2a  Section 6.3:  Adverse Event Definition and Reporting

Note:  Only the relevant paragraph from this section is included below, which is the third paragraph in the section.

Study site staff will document in source documents and the appropriate CRF all AEs (Grade 1 and higher) reported by or observed in enrolled study participants regardless of severity and presumed relationship to study product.  AE severity will be graded per the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009).  Version 2.0, November 2014.  This version will be used for the entire duration of the study.

Revision 2b  Section 6.4.2: Reporting Requirements for this Study

Note:  Only the relevant paragraph from this section is included below, which is the first paragraph under “Grading of Severity of Events”

Grading Severity of Events

The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, December 2004, clarification August 2009 (or latest version) must Version 2.0, November 2014, will be used for the entire duration of the study for determining and reporting the severity of adverse events.  The DAIDS grading table is available on the DAIDS RSC website at http://rsc.techres.com/safetyandpharmacovigilance.